dm+d
Unassigned
New Medicines
Cardiovascular disorders; in patients with an implantable cardioverter defibrillator
Information
Licence extension / variation
Forest Labs
Forest Labs
Development and Regulatory status
None
None
Suspended
Mar 15: development appears to have stopped [1]
Category
Potassium channel antagonist
Cardiovascular disorders; in patients with an implantable cardioverter defibrillator
Oral
Trial or other data
Mar 15: Forest Laboratories terminated the SHIELD-2 phase III registrational trial in May 2013 (NCT01464476); no reasons were provided. The trial was required for US FDA approval of azimilide in ventricular arrhythmias; at the time of termination 240 patients had been enrolled. [1]